Interactive R&D portfolio
MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.
The MMV project portfolio is updated quarterly. Click on a project below for more information.
- Download MMV's portfolio at end of 1st quarter, 2013 [360Kb]
- Download the global malaria portfolio at end of 1st quarter, 2013. [115Kb]
- Download the global malaria portfolio, classified by therapeutic type at end of 1st quarter, 2013 [520Kb]
For more information about the global malaria portfolio, read the article: The Global Portfolio of New Antimalarial Medicines Under Development.
Research
Lead generation
Lead optimization
Translational
Preclinical
Phase I
Phase IIa
Development
Phase IIb/III
Registration
Phase IV
Legend
MP - miniportfolio: MMV pioneered the miniportfolio model. The model assures flexibility in allocation of resources – established between MMV and a Pharmaceutical or Biotechnology partner – from one project to another. In this way, resources are utilized as efficiently as possible.
- Included in MMV portfolio post registration.